Q2 FY2026 · ended Jun 30, 2026 · Revenue $9.24M, -19.6% YoY · Filed Aug 13, 2026
Gossamer Bio, Inc. (GOSS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $9.2 million and net income of $16.9 million. Free cash flow was -$39.4 million. As of Jun 30, 2026 it held $57.0 million in cash and investments and $3.9 million in total debt.
Revenue
$9.24M
-19.6% vs year-ago quarter
Net income
$16.90M
+144.2% vs year-ago quarter
Operating cash flow
$-39.42M
+16.2% vs year-ago quarter
Free cash flow
$-39.42M
+16.3% vs year-ago quarter
EPS
$-0.08
+52.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
488.85M
+115.0% vs year-ago quarter
Net cash
$53.10M
Q2 FY2026
Operating margin
-311.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOSS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1728117
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $9.2M | $17.0M | $13.8M | $13.3M | $11.5M |
| Operating income | -$26.1M | -$44.9M | -$46.0M | -$49.1M | -$38.8M |
| Net income | $16.9M | -$46.7M | -$47.2M | -$48.2M | -$38.3M |
| Diluted EPS | -$0.08 | -$0.20 | -$0.20 | -$0.21 | -$0.17 |
| Operating cash flow | -$39.4M | -$38.7M | -$48.3M | -$36.2M | -$47.1M |
| Free cash flow | -$39.4M | -$38.7M | -$48.3M | -$36.2M | -$47.1M |
| Total assets | $76.9M | $128.9M | $172.2M | $208.8M | $240.9M |
| Total liabilities | $170.9M | $290.4M | $295.0M | $291.2M | $287.0M |
| Stockholders' equity | -$94.0M | -$161.5M | -$122.8M | -$82.3M | -$46.1M |
| Cash and investments | $57.0M | $99.2M | $136.9M | $180.2M | $212.9M |
| Total debt | $3.9M | $4.2M | $4.4M | $4.6M | $4.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 28, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
All 484 Gossamer Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.